Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in DMARD-naive Psoriatic Arthritis
NCT01307423Phase 3Completed
- Sponsor
- Amgen
- Start
- Dec 2010
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of apremilast in psoriatic arthritis (PsA), sponsored by Amgen. Started Dec 2010; status: completed.
02
Drugs
apremilast
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT01307423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01307423.